OncoMatch/Clinical Trials/NCT07189871
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Is NCT07189871 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies 177Lu-BetaBart for castration-resistant prostate cancer (crpc).
Treatment: 177Lu-BetaBart — A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Colorectal Cancer
Non-Small Cell Lung Carcinoma
Ovarian Cancer
Cervical Cancer
Endometrial Cancer
Triple-Negative Breast Cancer
Breast Carcinoma
Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
Esophageal Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: lu-177-psma radioligand therapy
Lab requirements
Blood counts
Platelet count ≥ 100 x 10^9/L; ANC ≥ 1.5 x 10^9/L; Hemoglobin ≥ 9 g/dL
Kidney function
eGFR ≥ 50 mL/min (CKD-EPI 2021)
Liver function
ALT or AST ≤ 3 x ULN (≤ 5 x ULN with liver metastases); total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN with Gilbert's syndrome)
Cardiac function
No unstable angina, MI within 6 months, NYHA Class II+ CHF, significant arrhythmia, LVEF < 50%, QTcF > 480 msec, or congenital long QT syndrome
Inadequate organ functions as reflected in laboratory parameters: eGFR < 50 mL/min; Platelet count < 100 x 10^9/L; ANC < 1.5 x 10^9/L; Hemoglobin < 9 g/dL; ALT or AST > 3 x ULN (> 5 x ULN with liver metastases); Total bilirubin > 1.5 x ULN, except for participants with documented Gilbert's syndrome who are eligible if total bilirubin ≤ 3 x ULN; cardiac: see cardiovascular exclusion criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dothan Hematology & Oncology · Dothan, Alabama
- BAMF Health · Grand Rapids, Michigan
- Nebraska Cancer Specialists · Omaha, Nebraska
- XCancer · Omaha, Nebraska
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify